Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease – a study within the Europe Against Cancer Program
暂无分享，去创建一个
T. Lion | J. Dongen | N. Boeckx | M. González | E. Gottardi | G. Barbany | W. Hop | E. Beillard | N. Pallisgaard | M. Malec | P. Hoogeveen | J. Gabert | V. D. Velden | Nancy Boeckx | Marta González | Gisela Barbany | Thomas Lion | Enrico Gottardi | Niels Pallisgaard | W. Hop
[1] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[2] F. Watzinger,et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program , 2003, Leukemia.
[3] J. Gabert,et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects , 2003, Leukemia.
[4] D. Ruff,et al. Substantial changes in gene expression level due to the storage temperature and storage duration of human whole blood. , 2002, Clinical and laboratory haematology.
[5] A. Órfão,et al. Minimal residual disease in leukaemia patients. , 2001, The Lancet. Oncology.
[6] G. Morgan,et al. Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. , 2000, Blood.
[7] P. Hokland,et al. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real‐time RT‐PCR exemplified by t(12;21) TEL‐AML1 fusion transcript , 1999, Genes, chromosomes & cancer.